[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment",
    "summary": "On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market presence. This announcement, alongside FDA approval in December 2024, likely bolstered the company's recent stock performance. Over the last quarter, Vertex's share price increased by 5.11%, despite broader market challenges, including economic slowdown concerns and significant...",
    "url": "https://finnhub.io/api/news?id=2fc3a7185c0a06dc522f00a8f8c0574fd2384f39cc4a0c5d774bf4567d7db20a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741368084,
      "headline": "Vertex Pharmaceuticals (NasdaqGS:VRTX) Gains UK Approval For New Cystic Fibrosis Treatment",
      "id": 133185506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "On March 7, 2025, Vertex Pharmaceuticals (NasdaqGS:VRTX) announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its market presence. This announcement, alongside FDA approval in December 2024, likely bolstered the company's recent stock performance. Over the last quarter, Vertex's share price increased by 5.11%, despite broader market challenges, including economic slowdown concerns and significant...",
      "url": "https://finnhub.io/api/news?id=2fc3a7185c0a06dc522f00a8f8c0574fd2384f39cc4a0c5d774bf4567d7db20a"
    }
  },
  {
    "ts": null,
    "headline": "Update: Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary",
    "summary": "(Updates with response from Optum Rx in the third and fourth paragraphs.) Vertex Pharmaceuticals",
    "url": "https://finnhub.io/api/news?id=f7d26d5921ea51db6bab7ddf6b0145d4cae7e9052350a1779efc76b8c22ed480",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741366445,
      "headline": "Update: Vertex Pharmaceuticals Says Journavx Non-Opioid Pain Killer Added to Optum Formulary",
      "id": 133185507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "(Updates with response from Optum Rx in the third and fourth paragraphs.) Vertex Pharmaceuticals",
      "url": "https://finnhub.io/api/news?id=f7d26d5921ea51db6bab7ddf6b0145d4cae7e9052350a1779efc76b8c22ed480"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "LONDON, March 07, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutati",
    "url": "https://finnhub.io/api/news?id=1251a4cafcf44197e53e4c931b5d097ffee17b4c065c31c589954a067031a8f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741359720,
      "headline": "Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 133185508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "LONDON, March 07, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator treatment for people living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutati",
      "url": "https://finnhub.io/api/news?id=1251a4cafcf44197e53e4c931b5d097ffee17b4c065c31c589954a067031a8f7"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge All Cap Growth Strategy Q4 2024 Commentary",
    "summary": "The ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in the fourth quarter. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=81b2942b352a432f4c8934f624e12169c63abda471c2d5a524050f1bd70c8ce0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741340400,
      "headline": "ClearBridge All Cap Growth Strategy Q4 2024 Commentary",
      "id": 133090333,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413858192/image_1413858192.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "The ClearBridge All Cap Growth Strategy underperformed its Russell 3000 Growth Index benchmark in the fourth quarter. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=81b2942b352a432f4c8934f624e12169c63abda471c2d5a524050f1bd70c8ce0"
    }
  }
]